John Murphy, MD., M.P.H., D.P.H., President COVID Long-haul Foundation
Abstract
Long COVID, also termed post-acute sequelae of SARS-CoV-2 infection (PASC), has emerged as one of the defining chronic illnesses of the post-pandemic era. Although fatigue, dyspnea, dysautonomia, and neurocognitive impairment dominate the literature, chronic diffuse itching and persistent dermatologic injury represent increasingly recognized manifestations of prolonged immune dysregulation following SARS-CoV-2 infection. Patients frequently describe relentless pruritus, burning dysesthesia, papular eruptions, urticarial lesions, vasculitic rashes, livedoid changes, acral ischemia, and neurocutaneous hypersensitivity that persist months or years after acute infection. In severe cases, pruritus becomes debilitating, causing insomnia, autonomic instability, psychiatric distress, malnutrition, excoriations, and profound loss of quality of life.
This monograph reviews the evolving evidence linking long COVID with chronic pruritus and cutaneous pathology. Particular attention is directed toward immune activation, mast cell dysfunction, microvascular injury, persistent viral reservoirs, endothelial inflammation, cytokine dysregulation, neuropathic itch, autonomic dysfunction, and small fiber neuropathy. The article further explores the clinical progression of long COVID-associated dermatologic syndromes, discusses papules, vesicular lesions, purpura, chilblain-like eruptions, urticaria, eczema-like presentations, and diffuse inflammatory dermatoses, and evaluates current and emerging therapeutic strategies. Evidence from peer-reviewed literature suggests that persistent itching in long COVID represents not merely a superficial dermatologic nuisance but rather a complex neuroimmunologic disorder involving the skin, peripheral nervous system, vasculature, and immune system simultaneously.
Introduction
The emergence of SARS-CoV-2 transformed modern medicine. Initial clinical attention focused primarily upon acute respiratory compromise, thrombosis, and mortality; however, by late 2020 clinicians across multiple disciplines began recognizing a persistent post-viral syndrome affecting millions worldwide. Patients who survived the acute infection frequently reported exhaustion, dysautonomia, cognitive impairment, sensory abnormalities, palpitations, exercise intolerance, gastrointestinal disturbances, and diffuse inflammatory symptoms months after apparent recovery.[1–4]
Among the most underrecognized yet profoundly disabling manifestations has been chronic pruritus. Many long COVID patients describe diffuse itching without obvious rash, while others develop persistent papules, urticarial plaques, vesicular eruptions, vasculitic lesions, eczema-like dermatitis, burning skin, or painful neuropathic hypersensitivity.[5–8] Some individuals experience severe nocturnal pruritus accompanied by insomnia and autonomic activation. Others develop chronic dermatographism, mast-cell-like reactions, heat sensitivity, or diffuse inflammatory eruptions that wax and wane in parallel with systemic symptoms.
Historically, chronic pruritus has been associated with hepatic disease, renal insufficiency, hematologic malignancy, autoimmune disorders, cholestatic syndromes, endocrinopathies, medication reactions, and neuropathic disorders. Long COVID now appears to join this list.[9] Importantly, itching in post-COVID syndromes frequently demonstrates features distinct from ordinary allergic disease. Many patients fail antihistamines, exhibit normal eosinophil counts, and display evidence of autonomic dysfunction, neuroinflammation, or small fiber neuropathy instead.
Emerging evidence suggests that SARS-CoV-2 can induce persistent immune activation long after acute infection resolves. Viral remnants, dysregulated cytokine production, endothelial injury, mast-cell activation, complement dysregulation, and autoantibody generation may together sustain chronic inflammation.[10–14] In parallel, injury to peripheral sensory nerves may transform ordinary tactile sensation into burning itch or dysesthetic pain.
The skin functions not merely as a passive barrier but as an active neuroimmunologic organ. Keratinocytes, mast cells, dendritic cells, endothelial cells, sensory neurons, and immune mediators continuously communicate through cytokines, neuropeptides, and inflammatory cascades. SARS-CoV-2 appears capable of perturbing this delicate network in susceptible individuals.[15]
The result can be devastating. Patients frequently report social isolation, depression, sleep deprivation, excoriation injuries, inability to tolerate clothing, and profound psychological exhaustion. In severe cases, diffuse pruritus becomes a life-altering chronic illness.
Epidemiology of Long COVID Dermatologic Manifestations
Long COVID affects an estimated 10–30% of infected individuals depending upon the population studied and the diagnostic criteria utilized.[16] Cutaneous manifestations are less common than fatigue or dyspnea yet remain clinically significant. Meta-analyses suggest that dermatologic symptoms persist in a substantial minority of long COVID patients months after acute infection.[17]
The precise prevalence of chronic pruritus remains uncertain because dermatologic symptoms are frequently underreported or classified nonspecifically. Several cohort studies have documented persistent urticaria, papulosquamous eruptions, pernio-like lesions, diffuse itching, alopecia, eczema-like dermatitis, and vasculitic changes lasting beyond twelve weeks.[18]
Women appear disproportionately affected, particularly middle-aged women with preexisting autoimmune tendencies or allergic disease.[19] Nevertheless, severe cases have been documented across all age groups, including previously healthy individuals with mild acute infections.
Notably, chronic pruritus may occur after asymptomatic or minimally symptomatic acute COVID-19. This observation supports the hypothesis that persistent immune dysregulation rather than acute tissue destruction alone drives many long COVID manifestations.
Dermatologic symptoms may arise immediately after infection or emerge months later. Patients frequently describe relapsing-remitting patterns associated with stress, exertion, heat exposure, alcohol, vaccination, reinfection, hormonal fluctuations, or secondary infections.
The Skin as an Immunologic Organ
Understanding long COVID-associated itching requires appreciation of the skin as a highly active immune interface.
The epidermis contains keratinocytes capable of producing cytokines including IL-1, IL-6, TNF-α, and interferons. Mast cells populate the dermis and release histamine, tryptase, prostaglandins, leukotrienes, and neuroactive compounds during immune activation. Sensory neurons express receptors sensitive to inflammatory mediators and communicate bidirectionally with immune cells.
Pruritus is generated through specialized unmyelinated C-fibers and thinly myelinated Aδ fibers that transmit itch signals to the spinal cord and brain. Cytokines such as IL-31, IL-4, IL-13, thymic stromal lymphopoietin, substance P, and nerve growth factor amplify itch signaling.[20]
COVID-19 perturbs this environment profoundly. Endothelial inflammation, complement activation, cytokine excess, coagulation abnormalities, mast-cell degranulation, and neural injury create conditions favorable for chronic pruritus and inflammatory dermatoses.
Etiology and Mechanisms of Chronic Itching in Long COVID
Persistent Viral Reservoirs
One leading hypothesis proposes that SARS-CoV-2 viral fragments persist within tissues long after acute infection.[21] Viral RNA and proteins have been identified in gastrointestinal tissue, lymphoid tissue, vascular endothelium, and other organs months following infection.
Persistent viral antigens may continuously stimulate innate and adaptive immunity, producing chronic cytokine release and inflammatory signaling. In the skin, persistent immune activation may drive mast-cell degranulation, endothelial inflammation, and neuropathic sensitization.
Some investigators speculate that viral persistence within cutaneous endothelial cells or peripheral nerves could directly contribute to chronic itching and dysesthesia.
Mast Cell Activation
Mast-cell activation syndrome (MCAS)-like pathology has received increasing attention in long COVID.[22] Mast cells express ACE2 receptors and can be activated directly or indirectly by viral infection.
Activated mast cells release histamine, tryptase, prostaglandins, leukotrienes, platelet-activating factor, cytokines, and chemokines. These mediators increase vascular permeability, activate sensory nerves, and induce intense pruritus.
Patients frequently report flushing, urticaria, dermatographism, temperature intolerance, palpitations, diarrhea, and episodic inflammatory flares suggestive of mast-cell dysregulation.
Importantly, some patients demonstrate mast-cell symptoms despite normal tryptase levels. Conventional laboratory markers may therefore underestimate mast-cell involvement.
Cytokine Dysregulation
Long COVID has been associated with persistent elevation of IL-6, TNF-α, IFN-γ, IL-1β, and other inflammatory mediators.[23] These cytokines influence peripheral sensory neurons and can directly amplify itch signaling.
IL-31 in particular has emerged as a central mediator of chronic pruritus in inflammatory skin disease. Elevated IL-31 activity may contribute to refractory itching in long COVID patients with papular eruptions or eczema-like syndromes.
Chronic cytokine activation may also perpetuate neuroinflammation, autonomic instability, fatigue, and cognitive dysfunction.
Small Fiber Neuropathy
Small fiber neuropathy (SFN) has increasingly been documented after COVID-19.[24] Damage to small sensory nerve fibers may generate burning pain, tingling, dysesthesia, thermal hypersensitivity, and neuropathic itch.
Neuropathic itch differs from allergic itch. Patients frequently describe electric sensations, crawling feelings, deep internal itching, or burning discomfort without visible rash.
Skin biopsies in some long COVID patients demonstrate reduced intraepidermal nerve fiber density. Autonomic dysfunction often coexists because autonomic fibers are similarly affected.
Autonomic and Vascular Dysfunction
Autonomic instability leads to episodic vasoconstriction and vasodilation, producing cycles of tissue hypoxia and reperfusion injury.
Patients frequently report symptom exacerbation with standing, heat exposure, and stress.
These vascular fluctuations amplify immune and neural sensitization within the skin.
Sleep and Feedback Loops
Sleep disruption is both a cause and consequence of chronic itch. Nocturnal sympathetic activation increases symptom severity, while sleep deprivation lowers itch thresholds.
This creates a self-reinforcing cycle of pruritus and insomnia.
Therapeutic Framework
Treatment requires multimodal therapy:
- Antihistamines and topical agents for peripheral symptoms
- Gabapentin, TCAs, SNRIs for neural sensitization
- Biologics targeting IL-4/IL-13 pathways in inflammatory phenotypes
- Autonomic stabilization (hydration, compression, graded activity)
- Sleep restoration strategies
Combination therapy is more effective than monotherapy.
Disease Trajectories
Three outcomes are observed:
- Gradual resolution over 12–36 months
- Relapsing-remitting disease triggered by stressors
- Chronic refractory disease associated with small fiber neuropathy
Severity Stratification
Severity is determined by itch intensity, neurologic involvement, autonomic instability, and dermatologic burden.
Mild disease is intermittent, moderate involves daily symptoms, and severe disease includes continuous multisystem impairment.
Differential Diagnosis
Important alternatives include:
- Atopic dermatitis
- Cholestatic pruritus
- Chronic kidney disease-related itch
- Brachioradial pruritus
- Psychogenic pruritus
Long COVID is distinguished by multisystem overlap of immune, neural, and autonomic dysfunction.
Limitations
Current evidence is primarily observational. Biomarkers are nonspecific, and no validated diagnostic test exists. Long-term outcomes remain uncertain.
Future Directions
Research priorities include biomarker validation, longitudinal cohort studies, and randomized controlled trials of multimodal therapies.
Single-cell immune profiling and autonomic mapping may refine disease classification into mechanistic endotypes.
Conclusion
Long COVID-associated chronic pruritus represents a complex neuroimmune-vascular syndrome characterized by persistent interaction between immune activation, neural sensitization, and autonomic dysregulation. It requires multidisciplinary management and further mechanistic study.
References
Raj SR, Arnold AC, Barboi A, et al. Long-COVID postural tachycardia syndrome. Nature Reviews Cardiology. 2021;18
Davis HE, McCorkell L, Vogel JM, et al. Long COVID: major findings, mechanisms and recommendations. Nature Reviews Microbiology. 2023;21:133–146.
Mehandru S, Merad M. Pathological sequelae of long-haul COVID. Nature Immunology. 2022;23:194–202.
Crook H, Raza S, Nowell J, et al. Long covid—mechanisms, risk factors, and management. BMJ. 2021;374:n1648.
Aiyegbusi OL, Hughes SE, Turner G, et al. Symptoms, complications and management of long COVID. Journal of the Royal Society of Medicine. 2021;114(9):428–442.
Natarajan A, Shetty A, Delanerolle G, et al. Systematic review and meta-analysis of long COVID symptoms. Systematic Reviews. 2023;12:88.
Galván Casas C, Català A, Carretero Hernández G, et al. Classification of the cutaneous manifestations of COVID-19. British Journal of Dermatology. 2020;183:71–77.
Freeman EE, McMahon DE, Lipoff JB, et al. The spectrum of COVID-19-associated dermatologic manifestations. Journal of the American Academy of Dermatology. 2020;83:1118–1129.
Marzano AV, Cassano N, Genovese G, et al. Cutaneous manifestations in patients with COVID-19. Journal of the American Academy of Dermatology. 2020;83:880–889.
Ständer S. Chronic pruritus: clinical classification and management. Clinical and Experimental Dermatology. 2019;44:399–404.
Su Y, Yuan D, Chen DG, et al. Multiple early factors anticipate post-acute COVID-19 sequelae. Cell. 2022;185:881–895.
Peluso MJ, Deeks SG. Early clues regarding the pathogenesis of long-COVID. Trends in Immunology. 2022;43:268–270.
Proal AD, VanElzakker MB. Long COVID or post-acute sequelae of COVID-19. Frontiers in Microbiology. 2021;12:698169.
Pretorius E, Vlok M, Venter C, et al. Persistent clotting protein pathology in long COVID. Cardiovascular Diabetology. 2021;20:172.
Choutka J, Jansari V, Hornig M, Iwasaki A. Unexplained post-acute infection syndromes. Nature Medicine. 2022;28:911–923.
Steinhoff M, Schmelz M, Szabó IL, et al. Neurophysiological mechanisms of pruritus. Frontiers in Medicine. 2018;5:166.
Nalbandian A, Sehgal K, Gupta A, et al. Post-acute COVID-19 syndrome. Nature Medicine. 2021;27:601–615.
Lopez-Leon S, Wegman-Ostrosky T, Perelman C, et al. More than 50 long-term effects of COVID-19. Scientific Reports. 2021;11:16144.
McMahon DE, Gallman AE, Hruza GJ, et al. Long COVID in the skin. Lancet Infectious Diseases. 2021;21:e13–e14.
Sudre CH, Murray B, Varsavsky T, et al. Attributes and predictors of long COVID. Nature Medicine. 2021;27:626–631.
Mollanazar NK, Smith PK, Yosipovitch G. Mediators of chronic pruritus. Clinical Dermatology. 2016;34:241–248.
Swank Z, Senussi Y, Manickas-Hill Z, et al. Persistent circulating SARS-CoV-2 spike is associated with post-acute COVID-19 sequelae. Clinical Infectious Diseases. 2023;76:e487–e490.
Afrin LB, Weinstock LB, Molderings GJ. COVID-19 hyperinflammation and mast cell activation characteristics. International Journal of Infectious Diseases. 2020;100:327–332.
Schultheiß C, Willscher E, Paschold L, et al. The IL-1β, IL-6, and TNF cytokine axis in long COVID. Nature Immunology. 2022;23:1254–1261.
Oaklander AL, Mills AJ, Kelley M, et al. Peripheral neuropathy evaluations in patients with prolonged long COVID symptoms. Neurology: Neuroimmunology & Neuroinflammation. 2022;9:e1146.